NeuroDerm (NDRM) Takes Off on Promising Drug Trials

Shares of Rehovot, Israel, based NeuroDerm Ltd. (NDRM) rocketed on Tuesday, against the backdrop of a generally lower day in stocks overall. NeuroDerm’s stock was up by a market-leading 193.53%, rising $11.96 per share, to close at $18.14, on volume of 41,008,653 shares. The company reported positive mid-stage trial results for its Parkinson’s disease candidate. Founded Read the full article... Read the rest of NeuroDerm (NDRM) Takes Off on Promising Drug Trials at InvestorGuide.com .
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.